Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe ...( Emerging technology will potentia...)

Emerging technology will potentially enable access to MRI exams for

implantable cardiac device patients

NATICK, Mass. and BALTIMORE, April 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) and Surgi-Vision, Inc., a privately held company, today announced a licensing and development arrangement for magnetic resonance imaging (MRI)-safe technology. Physician implanters have consistently mentioned MRI-safe cardiac devices as a primary unmet clinical need. Under the arrangement, Boston Scientific will gain access to Surgi- Vision's development capabilities and will obtain a license to Surgi-Vision's intellectual property for potential use in its implantable cardiac devices. The two companies will work jointly to develop a commercial application of Surgi-Vision's technology.

"Surgi-Vision is thrilled to have entered into this agreement with Boston Scientific as it represents a tremendous opportunity for both companies," said Kimble Jenkins, Chief Executive Officer of Surgi-Vision. "Our company is a leader in the development of MRI-safe technologies, and we look forward to applying our expertise to the field of cardiac rhythm management devices with Boston Scientific."

"This agreement with Surgi-Vision is consistent with our vision of providing physicians with the highest quality products for their patients," said Fred Colen, Executive Vice President, Operations and Technology, Boston Scientific Cardiac Rhythm Management. "Surgi-Vision's technology, when combined with our history of innovation, should move development of MRI-safe cardiac devices closer to reality."

Boston Scientific and Surgi-Vision entered into a separate licensing and development agreement, in the area of n
'/>"/>